Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing CD19-targeting CAR T-cell therapies for autoimmune diseases, and its news flow reflects this focus. Company updates frequently highlight progress with its lead autologous CAR T-cell therapy candidate, mivocabtagene autoleucel (miv-cel, KYV-101), in B-cell-driven autoimmune conditions.
Visitors to this KYTX news page can review announcements on Kyverna’s registrational trials in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). Recent press releases describe positive topline data from the KYSA-8 registrational Phase 2 trial in SPS and interim Phase 2 data from the KYSA-6 registrational Phase 2/3 trial in gMG, including reported effects on disability, mobility, and disease activity scores, as well as safety outcomes such as the absence of high-grade cytokine release syndrome or ICANS in the reported datasets.
News items also cover Kyverna’s broader development and financing activities. These include business updates and quarterly financial results, a loan facility with Oxford Finance LLC, and public equity offerings under an effective shelf registration statement on Form S-3. Additional releases describe investigator-initiated trials in multiple sclerosis and rheumatoid arthritis, Phase 1/2 trials in lupus nephritis, and the advancement of KYV-102, which the company characterizes as using a whole blood rapid manufacturing process.
Investors and followers of KYTX can use this page to track Kyverna’s press releases on clinical milestones, regulatory plans such as an anticipated BLA submission for SPS, corporate presentations at healthcare conferences, leadership and governance changes, and capital-raising transactions. Checking this feed provides a consolidated view of how the company reports its progress in autoimmune CAR T-cell therapy and related corporate developments.
Kyverna Therapeutics (NASDAQ: KYTX) will present new neuroimmunology data at the American Academy of Neurology (AAN) Annual Meeting, April 18-22, 2026 in Chicago.
Oral sessions include primary analysis from the registrational KYSA-8 trial in stiff person syndrome showing statistically significant clinical benefit and updated KYSA-6 Phase 2 results in generalized myasthenia gravis. Multiple posters cover real-world outcomes and Phase 3 design.
Kyverna Therapeutics (Nasdaq: KYTX) announced management will attend investor conferences in March 2026, including a Leerink fireside chat and Jefferies investor meetings.
The Leerink fireside chat is scheduled for March 9, 2026 at 11:20 a.m. ET; a live webcast and a 90-day replay will be available via the company investor website, according to the company.
Kyverna Therapeutics (Nasdaq: KYTX) announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors effective Feb. 24, 2026. Emany will serve as Audit Committee Chair following Dan Spiegelman’s departure from the board. The hires add finance, capital-markets, clinical development and product-approval experience as Kyverna advances autoimmune CAR T programs toward commercialization.
The company highlighted Emany’s CFO and investment-banking background and Miller’s R&D leadership and role in Karuna’s acquisition and KarXT development.
Kyverna Therapeutics (NASDAQ: KYTX) named Mayo Pujols as Chief Technology Officer, effective February 9, 2026, succeeding Karen Walker who will consult during the transition.
Pujols brings 30+ years in cell and gene therapy manufacturing. Kyverna disclosed an inducement option for 300,000 shares vesting over four years; grant tied to the closing stock price on the grant date.
Kyverna Therapeutics (NASDAQ: KYTX) provided a corporate update and 2026 priorities on Jan 12, 2026, highlighting late‑stage progress for its CAR T candidate miv‑cel. Key items: Kyverna plans to file a BLA for stiff person syndrome (SPS) in 1H 2026 after positive registrational topline data; the first patient has enrolled in the Phase 3 portion of the gMG KYSA‑6 trial; an IND for KYV‑102 was accepted by FDA in Jan 2026; a December 2025 follow‑on offering raised approximately $105M, and cash, cash equivalents, and marketable securities were ~$279M as of Dec 31, 2025, extending runway into 2028. Christi Shaw was appointed Executive Chairperson to strengthen CAR T commercialization experience.
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 14, 2026 at 9:45 a.m. PT.
Investors can access a live audio webcast via the company's Investors page at ir.kyvernatx.com. A replay will be available on the website for 30 days after the conference.
Kyverna Therapeutics (Nasdaq: KYTX) priced an underwritten public offering of 13,333,333 common shares at $7.50 per share to raise approximately $100 million gross, before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about December 18, 2025, and Kyverna granted a 30-day option for underwriters to buy up to 1,999,999 additional shares at the public offering price less underwriting discounts and commissions.
J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities are joint book-running managers. The securities are offered under an effective Form S-3 shelf registration declared effective on April 15, 2025.
Kyverna Therapeutics (Nasdaq: KYTX) announced a proposed underwritten public offering of $100,000,000 of common stock on December 15, 2025, with a 30-day underwriter option to purchase up to an additional $15,000,000 of shares at the public offering price, less underwriting discounts and commissions.
All shares will be sold by Kyverna and the offering is being led by J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities. The offering is subject to market and other conditions and will be made pursuant to an effective Form S-3 shelf registration (File No. 333-286180); a preliminary prospectus supplement will be filed with the SEC.
Kyverna Therapeutics (Nasdaq: KYTX) announced positive topline results from the registrational Phase 2 KYSA-8 trial of miv-cel (KYV-101) in stiff person syndrome (SPS) on December 15, 2025. In 26 dosed patients at the Week 16 primary analysis, miv-cel achieved a median 46% improvement in timed 25-foot walk (T25FW) vs baseline (p=0.0002) and 81% of patients exceeded a clinically meaningful 20% T25FW improvement. All secondary endpoints showed highly significant benefits (all p<0.0001).
Safety was manageable with no high-grade CRS or ICANS; Grade 3/4 neutropenia was observed. Kyverna plans a BLA submission in 1H 2026 and will present full data at a 2026 medical conference.
Kyverna Therapeutics (Nasdaq: KYTX) will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 AM ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS).
Registration is required to receive a dial-in number and unique PIN; the event can also be accessed via live webcast. Presentation materials will be posted in the Events & Presentations section of Kyverna's investor relations website and an archived replay will be available after the call.